Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target

Gene: ENO1

Summary for ENO1

Gene information	Gene symbol	ENO1
	Ensembl ID	ENSG00000074800
	Entrez ID	2023
	Gene name	enolase 1
	Synonyms	ENO1L1\|MBP-1\|MPB1\|PPH
	Gene type	protein_coding
	UniProtAcc	P06733

Top

Dataset with differentially expressed gene: ENO1

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE186960	Panc1 cell line	Cell line	Pancreatic cancer	Pancreatic ductal adenocarcinoma (PDAC)	Chemotherapy	gemcitabine	NA	Malignant cells	-0.544531	0.00e+00
GSE138267	CDX	Tumor tissue	Lung cancer	Small cell lung cancer (SCLC)	Chemotherapy	NA	NA	Malignant cells	0.629235	0.00e+00
GSE163836	FCIBC02 cell line	Cell line	Breast cancer	Inflammatory breast cancer	Chemotherapy	paclitaxel	NA	Malignant cells	-0.792308	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	-0.27905	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Mono/Macro	0.561184	5.35e-38
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	cDCs	0.496784	9.57e-07
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	cDCs	0.551042	3.59e-02
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	0.56587	1.30e-40
GSE153697	patients	Bone marrow aspirate	Acute lymphoblastic leukemia	Relapsed B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	anti-CD19 CAR-T	NA	Malignant cells	0.490161	7.53e-34
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Mono/Macro	0.295219	2.04e-36
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	cDCs	0.450052	1.89e-11
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD4+ T cells	0.336432	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	CD8+ T cells	0.294031	0.00e+00
GSE150930	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Mucosa-assisted lymphoid tissue (MALT) lymphoma	Immunotherapy	rituximab + cyclophosphamide + fludarabine	NA	Malignant cells	-0.422037	3.83e-18
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	0.43167	1.26e-14
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	0.513521	5.51e-14
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Malignant cells	0.669085	2.17e-07
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	0.49548	1.31e-19
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	B cells	0.425769	7.85e-05
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	-0.311313	1.03e-04
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	-0.477654	2.26e-11
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Malignant cells	-0.949195	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	Malignant cells	0.342114	3.65e-08
GSE161195	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	DARA-KRD (daratumumab + carfilzomib + lenalidomide + dexamethasone)	post	Malignant cells	0.439988	0.00e+00
GSE161195	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	DARA-KRD (daratumumab + carfilzomib + lenalidomide + dexamethasone)	pre	Malignant cells	0.287451	0.00e+00
GSE158457	PDX cells	Cell line	Acute lymphoblastic leukemia	T-cell acute lymphoblastic leukemia (ALL)	Targeted therapy	dasatinib	NA	Malignant cells	-1.20947	0.00e+00
GSE168668	LNCaP cell line	Cell line	Prostate cancer	Prostate cancer	Targeted therapy	enzalutamide	NA	Malignant cells	0.563881	0.00e+00
GSE149214	PC9 cell line	Cell line	Lung cancer	EGFR-mutated non-small cell lung cancer (NSCLC)	Targeted therapy	erlotinib	NA	Malignant cells	-0.370134	8.59e-31
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD4+ T cells	0.823594	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	NK cells	0.783504	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	1.32771	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	B cells	-1.13288	3.20e-08
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Erythrocytes	-0.390527	6.75e-03
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Malignant cells	0.263848	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD4+ T cells	-0.322989	1.33e-04
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD8+ T cells	-0.726297	5.94e-26
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	NK cells	0.344799	2.67e-16
GSE131984_JQ1	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1	NA	Malignant cells	-0.711833	0.00e+00
GSE131984_JQ1Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + paclitaxel	NA	Malignant cells	-0.557091	8.09e-40
GSE131984_JQ1Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + palbociclib	NA	Malignant cells	-1.24908	0.00e+00
GSE131984_Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	palbociclib	NA	Malignant cells	-0.661732	0.00e+00
GSE108397	451Lu cell line	Cell line	Melanoma	Melanoma	Targeted therapy	PLX-4720	NA	Malignant cells	-0.569081	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	Malignant cells	-0.498618	0.00e+00
GSE175716	PDX	Tumor tissue	Liver cancer	Advanced hepatocellular carcinoma	Targeted therapy	sorafenib	NA	Malignant cells	0.541183	0.00e+00
GSE164897_Vem	A375 cell line	Cell line	Melanoma	BRAFV600E-mutant melanoma	Targeted therapy	vemurafenib	NA	Malignant cells	0.259246	0.00e+00
GSE164897_VemTra	A375 cell line	Cell line	Melanoma	B+E2:E57RAFV600E-mutant melanoma	Targeted therapy	vemurafenib + trametinib	NA	Malignant cells	-1.55235	0.00e+00

Top

Expression of ENO1 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to ENO1

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Gene symbol	Mechanism
ENO1	Unusual Activation of Pro-survival Pathway

Page: 1

Top

MicroRNAs (miRNA) regulating ENO1

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
ENO1	hsa-miR-4521	84.1554	NM_001201483
ENO1	hsa-miR-6815-3p	80.2683	NM_001201483

Page: 1

Top

Motifs and transcription factors (TFs) regulating ENO1

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
ENO1	metacluster_7.13	ZFX (directAnnotation).
ENO1	cisbp__M01863	ZNF711 (inferredBy_Orthology).
ENO1	metacluster_170.2	KLF1; KLF10; KLF10; KLF11; KLF11; KLF11; KLF12; KLF12; KLF14; KLF15; KLF17; KLF2; KLF5; KLF7; KLF7; KLF8; MAZ; MAZ; PATZ1; SP1; SP1; SP1; SP2; SP2; SP2; SP2; SP2; SP2; SP2; SP2; SP4; SP4; SP5; SP6; SP7; SP8; SP9; ZNF281 (directAnnotation). E2F1; E2F4; KLF10; KLF13; KLF14; KLF17; KLF2; KLF7; SP1; SP1; SP3; SP4; SP5; SP6; SP7 (inferredBy_Orthology).
ENO1	metacluster_155.23	BCL11B; ZNF711; ZNF711 (directAnnotation). ZFY (inferredBy_Orthology).
ENO1	hdpi__ETV4	ETV4 (directAnnotation).
ENO1	metacluster_135.10	MBD2; MBD2; MECP2; MECP2 (directAnnotation).
ENO1	transfac_pro__M01219	SP1 (directAnnotation). SP3 (inferredBy_Orthology).
ENO1	transfac_pro__M07397	ZNF148 (directAnnotation).
ENO1	metacluster_131.7	EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR2; EGR2; EGR2; EGR2; EGR2; EGR2; EGR3; EGR3; EGR3; EGR3; EGR3; EGR3; EGR4; EGR4; WT1 (directAnnotation). EGR1; EGR1; EGR1; EGR1; EGR1; EGR2; EGR2; EGR2; EGR2; EGR2; EGR3; EGR3; WT1; ZBTB43; ZBTB43; ZBTB43; ZBTB43; ZBTB5; ZBTB5; ZBTB5; ZBTB5; ZBTB7A; ZBTB7A; ZBTB7A; ZBTB7A; ZNF367; ZNF367; ZNF367; ZNF367; ZNF740; ZNF740; ZNF740; ZNF740 (inferredBy_Orthology).
ENO1	taipale_cyt_meth__ZNF281_NCCCCTCCCCCN_eDBD_meth	ZNF281 (directAnnotation).
ENO1	metacluster_15.2	E2F1; E2F1; E2F1; E2F1; E2F1; E2F3; E2F4; E2F4; E2F4; E2F6; E2F6; E2F6; E2F6; E2F6; E2F6; E2F6; E2F7; TFDP1; TFDP2; ZNF566; ZNF566; ZNF574 (directAnnotation). E2F3; E2F3; E2F4 (inferredBy_Orthology).
ENO1	metacluster_3.11	SP1; SP1; SP2; SP3; SP3; SP4 (directAnnotation).
ENO1	transfac_pro__M01175	ZBTB7B (directAnnotation).
ENO1	taipale_cyt_meth__ZNF460_NRMCGCCCCCCGN_eDBD_meth	ZNF460 (directAnnotation).
ENO1	metacluster_3.7	SP1; SP1; SP1; SP1; SP1; SP1; SP1; SP1; SP2; SP2; SP2; SP2; SP3; SP3; SP3; SP4; SP4; SP4; SP4; SP4; SP4; SP5 (directAnnotation).
ENO1	transfac_pro__M01303	SP1 (directAnnotation).
ENO1	transfac_pro__M01714	KLF15 (directAnnotation).
ENO1	hocomoco__PROX1_HUMAN.H11MO.0.D	PROX1 (directAnnotation).
ENO1	transfac_pro__M02089	E2F3 (directAnnotation).
ENO1	metacluster_3.14	WT1; WT1 (directAnnotation).
ENO1	metacluster_3.4	SP1; SP2; SP2; SP3 (directAnnotation).
ENO1	hocomoco__EGR4_HUMAN.H11MO.0.D	EGR4 (directAnnotation).
ENO1	metacluster_3.5	KLF14; KLF15; KLF15; KLF16 (directAnnotation).
ENO1	transfac_pro__M07436	WT1 (directAnnotation).
ENO1	transfac_pro__M02281	SP1 (directAnnotation).
ENO1	kznf__ZNF730_Imbeault2017_RP_RCADE	ZNF730 (directAnnotation).
ENO1	transfac_pro__M02898	SMAD3 (directAnnotation).
ENO1	transfac_pro__M07461	KLF1; KLF10; KLF11; KLF12; KLF13; KLF15; KLF16; KLF17; KLF2; KLF3; KLF4; KLF5; KLF6; KLF7; KLF8; KLF9 (directAnnotation).
ENO1	metacluster_50.1	BATF; BATF; BATF; BATF; BNC2; FOS; FOSB; FOSL1; FOSL1; IRF4; JUN; JUN; JUNB; JUNB; JUNB; JUNB; JUND; JUND; JUND; JUND; JUND; SMAD2; SMAD3 (directAnnotation). BATF; BATF; BATF; FOS; FOSL1; FOSL2; JDP2; JUN; JUN; JUND (inferredBy_Orthology).
ENO1	metacluster_157.2	ATF3; ATF3; ATF3; BACH1; BACH1; BACH1; BACH2; BACH2; BACH2; BACH2; BATF; BATF; BCL11A; FOS; FOS; FOS; FOS; FOS; FOS; FOSB; FOSL1; FOSL1; FOSL1; FOSL1; FOSL1; FOSL1; FOSL2; FOSL2; FOSL2; JDP2; JDP2; JDP2; JDP2; JDP2; JDP2; JDP2; JUN; JUN; JUN; JUN; JUN; JUNB; JUNB; JUNB; JUNB; JUNB; JUNB; JUND; JUND; JUND; JUND; JUND; JUND; JUND; JUND; JUND; MAF; MAFB; MAFF; MAFG; MAFK; NFE2; NFE2; NFE2; NFE2; NFE2; NFE2; NFE2L1; NFE2L1; NFE2L2; NFE2L3; ZNF3; ZSCAN5C (directAnnotation). FOSL1; JUN; JUN; JUN; JUNB; JUNB; JUND (inferredBy_Orthology).
ENO1	transfac_pro__M05474	ZNF639 (directAnnotation).
ENO1	transfac_pro__M06944	PRDM15 (directAnnotation).
ENO1	taipale_tf_pairs__GCM1_HOXA2_RTRSGGGNNTAATKR_CAP_repr	GCM1; HOXA2 (directAnnotation).
ENO1	transfac_pro__M06192	ZNF135 (directAnnotation).
ENO1	metacluster_22.18	BACH2 (inferredBy_Orthology).
ENO1	taipale_tf_pairs__TFAP4_DLX3_NNCAGCTGNNNNTAATKR_HT	DLX3; TFAP4 (directAnnotation).
ENO1	taipale_tf_pairs__ERF_DLX2_RSCGGAANNNNNYMATTA_CAP_repr_1	DLX2; ERF (directAnnotation).
ENO1	metacluster_22.19	NFE2 (directAnnotation).
ENO1	metacluster_22.37	BACH1 (directAnnotation).
ENO1	transfac_pro__M04856	BATF (directAnnotation).
ENO1	metacluster_22.13	MAFK (inferredBy_Orthology).
ENO1	metacluster_22.36	BACH2 (directAnnotation).
ENO1	taipale_tf_pairs__TEAD4_HOXB13_NTCGTAAAATGC_CAP	HOXB13; TEAD4 (directAnnotation).
ENO1	taipale_tf_pairs__TEAD4_HOXB13_CYAATAAAATGYN_CAP_repr	HOXB13; TEAD4 (directAnnotation).
ENO1	transfac_pro__M06949	EVX2 (directAnnotation).
ENO1	metacluster_22.32	NFE2L2 (directAnnotation).
ENO1	transfac_pro__M06084	ZNF208 (directAnnotation).
ENO1	metacluster_22.21	NFE2L2 (inferredBy_Orthology).
ENO1	cisbp__M02408	NR2E1 (inferredBy_Orthology).
ENO1	metacluster_22.30	NFE2L2 (directAnnotation).

Page: 1 2 3 4 5

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

Target name	Drug name	Drug ID	Drug type
ENO1	"Artenimol"	DB11638	small molecule
ENO1	"Copper"	DB09130	small molecule
ENO1	"Zinc acetate"	DB14487	small molecule
ENO1	"Zinc chloride"	DB14533	small molecule
ENO1	"Zinc sulfate, unspecified form"	DB14548	small molecule
ENO1	"Zinc"	DB01593	small molecule

Page: 1

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."